Marker for Prognosis of a Clinical Outcome of an Autologous Intervertebral Disc Cell Transplantation, for Progress Assessment/Progress Monitoring of an Autologous Intervertebral Disc Cell Transplantation, for Assessing the Quality of Intervertebral Disc Cells, for Assessing the Quality of an Implant and/or Medication for Novel Therapies (ATMP) for the Treatment of an Intervertebral Disc Defect, and for Diagnosis of an Intervertebral and/or Spinal Column Defect

A marker for use in vitro in the prediction of a clinical outcome of an autologous disc cell transplantation, in particular a matrix-associated autologous disc cell transplantation, and/or in the progress assessment/progress monitoring of an autologous disc cell transplantation, in particular a matrix-associated autologous disc cell transplantation, and/or in the assessment of the quality of intervertebral disc cells, preferably for an autologous disc cell transplantation, in particular for a matrix-associated autologous disc cell transplantation, and/or in the assessment of the quality of an implant and/or advanced therapy medicinal products for the treatment of an intervertebral disc defect and/or for the reconstruction of intervertebral disc tissue and/or in the diagnosis of an intervertebral disc defect, in particular a lumbar, preferably lumbar-sacral, intervertebral disc defect, and/or spinal column defect, characterized in that the marker is selected from the group consisting of CTX-I, CTX-II, NTX-I, CPII, VEGF, C2C, MMP-3, hyaluronic acid, TNF-alpha, IL-1ra, IL-4, COMP, YKL-40 and combinations of at least two of said markers.

An in vitro method for the prediction of a clinical outcome of an autologous disc cell transplantation, in particular a matrix-associated autologous disc cell transplantation, and/or progress assessment/progress monitoring of an autologous disc cell transplantation, in particular a matrix-associated autologous disc cell transplantation, and/or assessment of the quality of intervertebral disc cells, preferably for an autologous disc cell transplantation, in particular for a matrix-associated autologous disc cell transplantation, and/or assessment of the quality of an implant and/or advanced therapy medicinal products for the treatment of an intervertebral disc defect and/or for the reconstruction of intervertebral disc tissue and/or diagnosis of an intervertebral disc defect, in particular a lumbar, preferably lumbar-sacral, intervertebral disc defect, and/or spinal column defect, characterized in that a marker is used that is selected from the group consisting of CTX-I, CTX-II, NTX-I, CPII, VEGF, C2C, MMP-3, hyaluronic acid, TNF-alpha, IL-1ra, IL-4, COMP, YKL-40 and combinations of at least two of said markers.

An in vitro use of a marker for the prediction of a clinical outcome of an autologous disc cell transplantation, in particular a matrix-associated autologous disc cell transplantation, and/or progress assessment/progress monitoring of an autologous disc cell transplantation, in particular a matrix-associated autologous disc cell transplantation, and/or assessment of the quality of intervertebral disc cells, preferably for an autologous disc cell transplantation, in particular for a matrix-associated autologous disc cell transplantation, and/or assessment of the quality of an implant and/or advanced therapy medicinal products for the treatment of an intervertebral disc defect and/or for the reconstruction of intervertebral disc tissue and/or diagnosis of an intervertebral disc defect, in particular a lumbar, preferably lumbar-sacral, intervertebral disc defect, and/or spinal column defect, characterized in that the marker is selected from the group consisting of CTX-I, CTX-II, NTX-I, CPII, VEGF, C2C, MMP-3, hyaluronic acid, TNF-alpha, IL-1ra, IL-4, COMP, YKL-40 and combinations of at least two of said markers.